Journal of Bone Oncology最新文献

{"title":"Differential expression of CD74 and C1QB in jaw versus long bone osteosarcoma: Insights from animal models, public datasets and clinical cohorts","authors":"Lalan Zhang ,&nbsp;Jiaoyan Liu ,&nbsp;Shengjie Shao ,&nbsp;Xiang Liu ,&nbsp;Liqin Zhang ,&nbsp;Weihong Wang","doi":"10.1016/j.jbo.2026.100742","DOIUrl":"10.1016/j.jbo.2026.100742","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to investigate the differential expression of macrophage-related factors between jaw and long bone osteosarcoma, thereby providing potential candidates for future functional and mechanistic research.</div></div><div><h3>Methods</h3><div>Twenty-four Sprague-Dawley (SD) rats were randomly divided into control, jaw osteosarcoma, and long bone osteosarcoma groups. UMR106 cells were implanted subcutaneously in nude mice, then tumors were transplanted into rat jaw and tibial bone marrow to establish osteosarcoma models. Bone changes were observed using Micro-CT, while histological changes were examined with H&amp;E and Masson’s trichrome staining. Transcriptome sequencing identified differentially expressed genes (DEGs), with the top three genes selected using Cytohubba software. Survival analysis was performed using the GEPIA database. A retrospective analysis was conducted on jaw osteosarcoma patients and long bone osteosarcoma patients from November 2014 to June 2023. Finally, immunohistochemical staining validated the expression levels of relevant proteins in both animal and clinical tissue samples.</div></div><div><h3>Results</h3><div>Micro-CT revealed significant bone destruction in both osteosarcoma models. Histological analysis revealed high pleomorphism in osteosarcoma cells, predominantly spindle and polygonal shapes, with evident pathological mitosis. Transcriptome sequencing identified 414 DEGs, including the top three: <em>RT1-Da</em>, <em>CD74</em>, and <em>C1QB</em>. Survival analysis showed high expression of <em>CD74</em> and <em>C1QB</em> correlated positively with overall survival in patients with osteosarcoma. Immunohistochemistry demonstrated higher CD74 and C1QB expression in jaw osteosarcoma compared to long bone osteosarcoma in both rats and humans (<em>P</em> &lt; 0.05).</div></div><div><h3>Conclusion</h3><div>The expression levels of CD74 and C1QB were significantly higher in jaw osteosarcoma than in long bone osteosarcoma, suggesting that this differential expression may have clinical relevance for patient survival and warrants further investigation.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"57 ","pages":"Article 100742"},"PeriodicalIF":3.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146174050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological features and survival disparities between axial and appendicular skeletal Angiosarcoma: A SEER-based analysis using competing risk models","authors":"Zhenliang Hao ,&nbsp;Xuewei Zhang ,&nbsp;Ning Yao ,&nbsp;Kai Li ,&nbsp;Luxin Lou ,&nbsp;Xuan Zheng ,&nbsp;Zhiming Guo ,&nbsp;Jiabin Chen ,&nbsp;Xuzhu Chen","doi":"10.1016/j.jbo.2026.100740","DOIUrl":"10.1016/j.jbo.2026.100740","url":null,"abstract":"<div><h3>Background</h3><div> <!-->Primary angiosarcoma of bone (ASB) is a rare and aggressive primary bone tumor. The prognostic significance of anatomical location (axial vs. appendicular skeleton) remains poorly defined. This study aimed to compare clinicopathological features and survival outcomes between these two groups.</div></div><div><h3>Methods</h3><div> <!-->Patients diagnosed with primary ASB (1975–2019) were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Tumors were categorized as axial (spine, pelvis, ribs, skull) or appendicular (extremities). Overall survival was analyzed using Kaplan-Meier and Cox models. Cancer-specific mortality (CSM) was evaluated with Fine-Gray competing risk regression to calculate subdistribution hazard ratios (SHR).</div></div><div><h3>Results</h3><div> <!-->Among 458 patients, 162 (35.4%) had axial and 296 (64.6%) had appendicular tumors. Axial patients were older (median 63 vs. 46 years, p &lt; 0.001), had higher distant metastasis at diagnosis (43.2% vs. 29.1%, p = 0.002), and underwent surgery less frequently (37.0% vs. 81.1%, p &lt; 0.001). The 5-year overall survival was significantly worse for axial tumors (16.8% vs. 38.2%, p &lt; 0.001). The 5-year cumulative incidence of CSM was 69.5% for axial versus 50.8% for appendicular tumors (p &lt; 0.001). Multivariate analysis confirmed axial location as an independent predictor of higher CSM (SHR 1.62, 95% CI: 1.25–2.10, p &lt; 0.001) ,<!--> <!-->independent of the year of diagnosis.</div></div><div><h3>Conclusions</h3><div>Axial tumors represent a distinct high-risk subgroup characterized by limited surgical resectability and inferior survival. Anatomical location should be considered a critical stratification factor in clinical management and future trials.</div><div>Abbreviations: <strong>ASB,</strong> Primary angiosarcoma of the bone; <strong>SEER,</strong> Surveillance, Epidemiology, and End Results; <strong>OS,</strong> Overall Survival; <strong>CSS,</strong> Cancer-Specific Survival; <strong>CSD,</strong> Cancer-Specific Death; <strong>CIF,</strong> Cumulative Incidence Function; <strong>SHR,</strong> Subdistribution Hazard Ratio; <strong>CI,</strong> Confidence Interval; <strong>HR,</strong> Hazard Ratio.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"57 ","pages":"Article 100740"},"PeriodicalIF":3.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146079934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital spatial profiling of α-PD-1 treated breast cancer bone metastases reveals region-specific signaling and enrichment of immune-suppressive markers","authors":"Déja M. Grant ,&nbsp;Gwenyth J. Joseph ,&nbsp;Madeline Searcy ,&nbsp;Rachelle W. Johnson","doi":"10.1016/j.jbo.2026.100741","DOIUrl":"10.1016/j.jbo.2026.100741","url":null,"abstract":"<div><div>Bone is the most common and preferential site for breast cancer metastasis. Upon dissemination to the bone, breast cancer cells engraft into multiple niches, but it is unclear whether there are region-specific differences that may drive breast cancer progression in bone. We used a proteomic digital spatial profiling (DSP) approach to investigate which proliferation, cell death, and immune-related markers and pathways are enriched in immune and cancer cells residing 1) in the bone marrow or 2) along the endosteal surface, in an E0771, α-PD-1 treated pre-clinical model of breast cancer bone metastasis. We selected morphological markers to identify breast cancer cells and immune cells and applied a multiplexed set of probes targeting &gt;70 proteins to characterize breast cancer and immune cell signaling in the marrow and endosteal regions using a DSP platform. We found multiple immune suppressive markers were enriched in the endosteum, including Foxp3, CD163, CD27, Pd-1, and Pd-l1, while proliferation markers were enriched in tumor cells in the marrow, including p38 Mapk, pan-Ras, Mek1, and phospho-Erk1/2. These findings shed light on the niche-specific proteins and pathways that are activated in breast cancer bone metastases and establish a user-friendly highly multiplexed approach for spatial proteomics in pre-clinical models of bone metastasis.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"57 ","pages":"Article 100741"},"PeriodicalIF":3.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146174088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychosocial impact of COVID-19 pandemic on patients with solid malignancies and bone metastases (PsyCO-B): a multicentre prospective observational study","authors":"Paolo Taurisano ,&nbsp;Ester Cornacchia ,&nbsp;Maria Fara De Caro ,&nbsp;Vittorio Fusco ,&nbsp;Toni Ibrahim ,&nbsp;Anna Ragno ,&nbsp;Francesco Salonne ,&nbsp;Giulia Paparella ,&nbsp;Marta Betti ,&nbsp;Serena Penpa ,&nbsp;Maura Rossi ,&nbsp;Rossella Hakim ,&nbsp;Michela Pierini ,&nbsp;Camillo Porta ,&nbsp;Stella D’Oronzo","doi":"10.1016/j.jbo.2026.100744","DOIUrl":"10.1016/j.jbo.2026.100744","url":null,"abstract":"<div><h3>Background</h3><div>COVID-19 pandemic dramatically changed our daily habits. Patients with cancer, particularly those with bone metastases (BM), were among the most concerned individuals, due to both their clinical condition and social distancing.</div></div><div><h3>Objectives</h3><div>This study aimed to explore psychosocial effects of the pandemic on patients with BM, investigating the role of clinical severity, psychological symptoms, coping strategies, and perceived traumatic impact.</div></div><div><h3>Methods</h3><div>Six questionnaires were administered to patients with BM from three Institutions: Hospital Anxiety-Depression Scale, WHO Quality of Life-BREF, Attitude Toward Seeking Professional Psychological Help, Brief Illness Perception Questionnaire, Brief COPE, and Impact Event Scale-Revised (IES-R). Clinical, pathological, and socio-demographic data were collected and analyzed using descriptive statistics. Clinical severity was estimated by applying a specific prognostic model. Statistical analyses included correlations, linear regressions and mediation analyses.</div></div><div><h3>Results</h3><div>Clinical severity was significantly associated with depressive symptoms whereas the perceived traumatic impact of the COVID-19 pandemic was strongly associated with anxiety, the use of specific coping strategies (social support, avoidance and religiosity) and greater openness to psychological support. Mediation analysis showed that the IES-R mediates the relationship between subjective perception of illness and anxiety.</div></div><div><h3>Conclusions</h3><div>During the pandemic, depressive symptoms in patients with BM were mainly related to their specific clinical condition, whereas those associated with anxiety were mostly due to the experience of pandemic-associated trauma. The psychological impact of the pandemic influenced coping strategies and the request for support, regardless of the disease severity. These findings highlight the importance of psycho-oncological support focused on the patient’s experience and clinical condition.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"57 ","pages":"Article 100744"},"PeriodicalIF":3.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146167723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinically aligned whole-body MRI segmentation of skeletal metastases via Supervised Anatomical Pretraining","authors":"Joris Wuts ,&nbsp;Jakub Ceranka ,&nbsp;Nicolas Michoux ,&nbsp;Frédéric Lecouvet ,&nbsp;Jef Vandemeulebroucke","doi":"10.1016/j.jbo.2026.100745","DOIUrl":"10.1016/j.jbo.2026.100745","url":null,"abstract":"<div><div>In oncology practice, response assessment of metastatic disease requires reliable and reproducible quantification of measurable metastatic burden. Manual identification, segmentation, and volumetry of all lesions is labor-intensive and variable, limiting routine clinical adoption. An automated approach is therefore needed. Segmenting metastatic bone disease (MBD) on whole-body MRI (WB-MRI) is challenging because of the heterogeneous appearance and anatomical distribution of lesions, ambiguous boundaries, and the low volumetric prevalence of metastatic deposits within the body. Training robust machine learning models for this task requires large, well-annotated datasets that capture lesion variability. However, assembling such datasets demands substantial expert time and is prone to annotation error. Although self-supervised learning (SSL) can take advantage of large unlabeled datasets, the learned representations tend to remain generic and may miss the subtle anatomical and pathological features essential for accurate lesion detection.</div><div>In this work, we propose a Supervised Anatomical Pretraining (SAP) method that learns from a limited dataset of anatomical labels. First, an MRI-based skeletal segmentation model is developed and trained on WB-MRI scans from healthy individuals for high-quality skeletal delineation. Then, we compare its downstream efficacy in segmenting MBD on a cohort of 40 patients with metastatic prostate cancer, against a randomly initialized baseline and a state-of-the-art self-supervised method.</div><div>SAP significantly outperforms both the Baseline and SSL-pretrained models achieving a normalized surface Dice of 0.78 and a Dice coefficient of 0.66. The method achieved a lesion detection <span><math><msub><mrow><mi>F</mi></mrow><mrow><mn>2</mn></mrow></msub></math></span> score of 0.45, improving on 0.26 (Baseline) and 0.31 (SSL). When considering only clinically relevant lesions larger than 1 mL, SAP achieves a mean lesion level sensitivity of 0.89 at 0.46 false positives per exam, supporting reliable follow-up and treatment-response assessment.</div><div>Learning bone morphology from anatomy yields an effective and domain-relevant inductive bias that can be leveraged for the downstream segmentation task of bone lesions. These results highlight SAP’s clinical utility for standardized, high-sensitivity WB-MRI monitoring of skeletal metastases in routine bone oncology practice. All code and models are made publicly available.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"57 ","pages":"Article 100745"},"PeriodicalIF":3.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146174094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathological fractures as an adverse prognostic factor in chondrosarcoma: Results of a systematic review, meta-analysis and institutional case series","authors":"Julian P. Maier ,&nbsp;Ida Peiss ,&nbsp;Felix Klingler ,&nbsp;Nikos Karvouniaris ,&nbsp;Kilian Reising ,&nbsp;Hagen Schmal ,&nbsp;Georg W. Herget","doi":"10.1016/j.jbo.2025.100735","DOIUrl":"10.1016/j.jbo.2025.100735","url":null,"abstract":"<div><h3>Background</h3><div>Pathological fractures are recognized as a potential, adverse prognostic factor in primary bone sarcomas. While some studies suggest higher recurrence rates and reduced survival, robust data specific to chondrosarcoma (CS) remain limited. This study evaluates the prognostic relevance of pathological fractures (PF) in CS patients.</div></div><div><h3>Methods</h3><div>A systematic review and <em>meta</em>-analysis were conducted according to PRISMA guidelines. Eligible studies included patients with CS of the bone, with comparative groups based on fracture status and oncological outcomes. Study design, quality, and endpoints were assessed, and pooled <em>meta</em>-analysis was conducted. Additionally, clinical data from an institutional cohort was analyzed retrospectively.</div></div><div><h3>Results</h3><div>Nine studies, with a total of 1,185 patients and 245 PF cases, met the inclusion criteria. Meta-analysis revealed that PF status was significantly associated with inferior survival at 1–5 years (pooled OR 0.40; 95 % CI 0.26–0.62; p &lt; 0.0001). The increased risk of death was particularly evident in dedifferentiated CS (pooled HR 1.96; 95 % CI 1.46–2.63; p &lt; 0.00001). Institutional data supported these findings, that PF was associated with worse overall survival (HR 3.90; 95 % CI 0.69–21.98; p = 0.12) and progression-free survival (HR 3.17; 95 % CI 0.58–17.36; p = 0.18), although significance was limited by sample size.</div></div><div><h3>Conclusions</h3><div>Pathological fractures entail a significantly adverse prognosis in chondrosarcoma, particularly in high-grade and dedifferentiated subtypes and within the first 5 years of follow-up. Our institutional data corroborates <em>meta</em>-analysis findings. These results underscore the importance of personalized surgical management and intensive outcome monitoring for CS patients presenting with PF.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"56 ","pages":"Article 100735"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145698199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Doxorubicin induces bone loss and modifies multiple cell populations in vivo – Implications for modelling of bone metastasis","authors":"Veli Kaan Aydin ,&nbsp;Lubaid Saleh ,&nbsp;Penelope Dawn Ottewell ,&nbsp;Ingunn Holen","doi":"10.1016/j.jbo.2025.100736","DOIUrl":"10.1016/j.jbo.2025.100736","url":null,"abstract":"<div><div>Doxorubicin (DOX), commonly used to treat breast cancer, is associated with cardiotoxicity and has negative effects on other organ systems, including the skeleton. DOX-induced bone damage has been demonstrated in murine models; however, results are conflicting due to the use of different doses, schedules, and rat/mouse strains. As DOX is used to limit tumour progression in models of skeletal metastasis, it is paramount to determine how the agent affects the bone microenvironment in the relevant mouse strains, to enable correct interpretation of DOX effects in tumour studies. We have therefore investigated the effects of DOX on bone structure and a range of bone and bone marrow cell populations, comparing immunocompetent and immunocompromised mice.</div><div>Groups of 7-week-old female BALB/c and BALB/c Nude mice were treated with either saline (control), 4 or 6 mg/kg DOX weekly for four weeks. Effects on bone volume and structure was determined using <em>ex vivo</em> µCT, a panel of bone marrow cell populations were quantified by flow cytometry and osteoblast/osteoclast numbers were assessed using bone histomorphometry.</div><div>DOX caused trabecular bone loss, with immunocompetent BALB/c mice being more sensitive to DOX than the immunocompromised BALB/c nude counterparts. The 6 mg/kg dose of DOX altered the ratio of bone marrow immune and haematopoietic cell populations in both groups, increasing the numbers of hematopoietic cells and progenitors, decreasing B cells and increasing the number of neutrophils. Bone marrow macrophage and monocyte numbers were increased following DOX treatment in BALB/c nude mice only. Our data demonstrate that DOX impacts a number of cell types in the bone microenvironment, highlighting the importance of considering treatment-induced bone effects when using DOX in models of bone metastasis.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"56 ","pages":"Article 100736"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145798385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-life use of bone-targeting agents for bone metastases in France between 2009 and 2018: Results of the OPTIMOS study","authors":"Cyrille B. Confavreux ,&nbsp;Béatrice Bouvard ,&nbsp;Nicolas Girard ,&nbsp;Pauline Bosco-Levy ,&nbsp;Clarisse Marchal ,&nbsp;Maeva Nolin ,&nbsp;Eric Lehmann ,&nbsp;Gaelle Desameric ,&nbsp;Manon Belhassen","doi":"10.1016/j.jbo.2025.100738","DOIUrl":"10.1016/j.jbo.2025.100738","url":null,"abstract":"<div><h3>Aim</h3><div>To determine the use of bone-targeting agents (BTAs) in clinical practice in France and the occurrence of skeletal-related events (SREs) in cancer patients with bone metastases.</div></div><div><h3>Methods</h3><div>This study analysed data, recorded prospectively in a French National Health Insurance database, for patients who had a first diagnosis of bone metastases between 2009 and 2018.</div></div><div><h3>Results</h3><div>A total of 6,663 patients were analysed (mean age 69.7 ± 13.2 years, 53.2 % male) corresponding to 2,363 bone metastases only patients and 4,300 patients with SREs at inclusion. The most frequent primary cancers were breast (15.8 %), prostate (13.4 %), lung (12.6 %) and digestive cancer (10.6 %). Six-hundred and twenty-one patients (9.3 %) were treated with BTAs (52.7 % with denosumab). Median [IQR] time between inclusion and BTA initiation was similar with denosumab (3.3 months [1.2–7.9]) and bisphosphonates (3.3 months [1.2–8.7]). Patients with a SRE at inclusion and early BTA initiation (≤3 months) had a significative lower incidence of a second SRE at 12 months than those with late initiation (13.6 % [95 %CI: 8.1–20.4] vs. 21.6 % [14.8–29.2] respectively; p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>BTAs are underused in bone metastases patients in France. There is an urgent need to optimise bone metastases management in accordance with ESMO 2020 guidelines.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"56 ","pages":"Article 100738"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145939112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pilot study of separation surgery with intraoperative radiotherapy (IORT) for spine metastasis","authors":"Baiyi Liu ,&nbsp;Dongsheng Wang ,&nbsp;Jian Zhang ,&nbsp;Bo Huang ,&nbsp;Mingying Geng ,&nbsp;Peng Liu ,&nbsp;Yaoyao Liu","doi":"10.1016/j.jbo.2025.100737","DOIUrl":"10.1016/j.jbo.2025.100737","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to introduce a novel modified separation surgery combined with intraoperative radiotherapy (MSS-IORT) treatment strategy for spinal metastasis and evaluate its efficacy and safety.</div></div><div><h3>Methods</h3><div>A prospective study was conducted from January 2023 to June 2024. Patients with spinal metastasis exhibiting epidural spinal cord compression (ESCC) ≥ 2 grades and spinal instability neoplastic score (SINS) ≥ 7 were enrolled and underwent MSS-IORT. During the procedure, a dose of 8–10 Gy of IORT was administered to the tumor-invaded vertebrae segments during modified separation surgery. Pain intensity was assessed using the visual analog scale (VAS) preoperatively and at 1 week, 3 months, 6 months, and 12 months postoperatively. Neurological function was evaluated <em>via</em> the Frankel grade system, and functional status was measured using the Karnofsky performance scale (KPS) preoperatively and at 3, 6, and 12 months after surgery. Local control was evaluated based on X-ray, CT, or MRI examination. Survival time and perioperative complications were also documented.</div></div><div><h3>Results</h3><div>A total of 38 patients (median age: 60 years) with 46 involved vertebrae were treated with MSS-IORT. The mean operation time was 277.5 min, and the mean blood loss was 750 ml. After a mean follow-up of 174.5 days, the VAS score decreased significantly postoperatively and continued to decline over time. The KPS score increased significantly at 6 and 12 months, and the Frankel grade significantly improved at 12 months. Local control failure occurred in 3 patients, and 13 experienced adverse events without IORT.</div></div><div><h3>Conclusion</h3><div>The MSS-IORT strategy demonstrates both safety and efficacy, representing a promising treatment option for spine metastases, particularly in patients with ESCC grades ≥ 2 and SINS ≥ 7.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"56 ","pages":"Article 100737"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145939114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mri-based habitat and peritumoral radiomics for predicting the proliferative activity of stromal cells in giant cell tumor of bone","authors":"Jie Xia ,&nbsp;Kunming Jiang ,&nbsp;Jinyi Zhou ,&nbsp;Lei Cao ,&nbsp;Fan Xiao ,&nbsp;Jingxuan Jiang","doi":"10.1016/j.jbo.2025.100733","DOIUrl":"10.1016/j.jbo.2025.100733","url":null,"abstract":"<div><h3>Purpose</h3><div>This study aims to explore the feasibility of MRI-based habitat and peritumoral radiomics for predicting the proliferative activity of stromal cells in giant cell tumor of bone (GCTB)<strong>.</strong></div></div><div><h3>Material and methods</h3><div>A retrospective study was performed on 133 patients<!--> <!-->(102 in training cohort and 31 in validation cohort) diagnosed with GCTB<!--> <!-->from four centers. The tumor was meticulously segmented into three distinct habitat subregions using K-means clustering, incorporating a 1-pixel peritumoral expansion to capture the microenvironments surrounding the tumor. After feature extraction and selection, habitat, intratumoral and peritumoral models integrating three different machine learning classifiers were constructed respectively to identify GCTB patients with high and low proliferation. The performance of the models was assessed by receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA). SHAP analysis was utilized to enhance model interpretability.</div></div><div><h3>Results</h3><div>Among the eligible patients, 43 (32.3 %) diagnosed with high proliferative activity of stromal cells in GCTB by pathological diagnosis. Among all models tested in the validation cohort, the Logistic Regression (LR) algorithm for habitat model exhibited superior performance in the validation cohort (AUC: 0.956, 95 % CI: 0.887–1.000). The calibration curves and DCA exhibited fit for the habitat model while providing great clinical net benefit.</div></div><div><h3>Conclusion</h3><div>MRI-based habitat radiomics had the potential to predict the proliferative activity of stromal cells in GCTB. This model may help determine optimal treatment strategies and improve patient outcomes.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"56 ","pages":"Article 100733"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145749334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}